Related Experiment Video
Updated: Jun 17, 2026
07:40
Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
Emerging drugs for acute myocardial infarction
Chiara Lazzeri1, Roberto Tarquini, Serafina Valente
1University of Florence, Department of Heart and Vessels, Florence, Italy.
Expert Opinion on Emerging Drugs
|January 9, 2010
Summary
Emerging drugs for ST-elevation myocardial infarction (STEMI) management are reviewed, focusing on personalized pharmacological strategies. Balancing thrombotic and bleeding risks is crucial for optimizing patient outcomes in primary percutaneous coronary intervention.
Area of Science:
- Cardiology
- Pharmacology
- Interventional Cardiology
Background:
- ST-elevation myocardial infarction (STEMI) requires timely and effective pharmacological management.
- Emerging drugs offer new therapeutic avenues for STEMI patients undergoing primary percutaneous coronary intervention (PCI).
- Balancing antithrombotic and bleeding risks is a critical challenge in STEMI treatment.
Purpose of the Study:
- To review the pharmacological profile and clinical impact of novel drugs for STEMI management.
- To provide cardiologists with the latest evidence for early-phase STEMI patient care.
- To highlight the importance of personalized medical strategies in STEMI treatment.
Main Methods:
- Review of current literature on anticoagulant and antiplatelet therapies in STEMI.
- Analysis of factors influencing drug response, including genetic and non-genetic determinants.
- Consideration of patient-specific variables (age, sex, comorbidities) and complications.
Main Results:
- Established benefits of antiplatelet agents, with ongoing questions regarding variable platelet response.
- Importance of considering non-genetic factors (diet, drug interactions, clinical conditions) and genetic determinants for personalized therapy.
- Emerging areas include pharmacological options for reperfusion injury, metabolic aspects, and stem cell therapy.
Conclusions:
- Personalized medical strategies are essential for optimizing STEMI patient care.
- Clinicians must integrate new research findings with a comprehensive patient approach.
- Continuous updating on emerging drugs and treatment modalities is vital for cardiologists managing STEMI.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:30Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:30Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...